A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma
Public ClinicalTrials.gov record NCT02969408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3B, 12-week, multicenter, open-label study to evaluate the relationship between albuterol sulfate (ABS) eMDPI and clinical asthma exacerbation (CAE) in adult participants at least 18 years of age with exacerbation-prone asthma. The ABS eMDPI dose will be 90 micrograms (mcg), 1 to 2 inhalations every 4 hours as needed, but participant dosing will not be limited to this dosing regimen. The purpose of this study is to evaluate the relationship between albuterol dosing and CAE.
Study identification
- NCT ID
- NCT02969408
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 397 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 13, 2017 (Actual)
- Primary completion
- Feb 2, 2018 (Actual)
- Completion
- Feb 2, 2018 (Actual)
- Last update posted
- Nov 9, 2021
2017 – 2018
United States locations
- U.S. sites
- 44
- U.S. states
- 23
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 13964 | Litchfield Park | Arizona | 85340 | — |
| Teva Investigational Site 13959 | Bakersfield | California | 93301 | — |
| Teva Investigational Site 13954 | Los Angeles | California | 90048 | — |
| Teva Investigational Site 13923 | Orange | California | 92868 | — |
| Teva Investigational Site 13961 | Riverside | California | 92506 | — |
| Teva Investigational Site 13933 | Centennial | Colorado | 80112 | — |
| Teva Investigational Site 13946 | Clearwater | Florida | 33765 | — |
| Teva Investigational Site 13921 | Loxahatchee Groves | Florida | 33470 | — |
| Teva Investigational Site 13942 | Miami | Florida | 33176 | — |
| Teva Investigational Site 13927 | Miami | Florida | 33186 | — |
| Teva Investigational Site 13948 | Orlando | Florida | 32803 | — |
| Teva Investigational Site 13934 | Orlando | Florida | 32819 | — |
| Teva Investigational Site 13931 | Ormond Beach | Florida | 32174 | — |
| Teva Investigational Site 13926 | Sarasota | Florida | 34239 | — |
| Teva Investigational Site 13963 | Savannah | Georgia | 31406 | — |
| Teva Investigational Site 13943 | Michigan City | Indiana | 46360 | — |
| Teva Investigational Site 13925 | Overland Park | Kansas | 66210 | — |
| Teva Investigational Site 13958 | Fort Mitchell | Kentucky | 41017 | — |
| Teva Investigational Site 13940 | Owensboro | Kentucky | 42301 | — |
| Teva Investigational Site 13937 | Bangor | Maine | 04401 | — |
| Teva Investigational Site 13965 | St Louis | Missouri | 63141 | — |
| Teva Investigational Site 13919 | Missoula | Montana | 59808 | — |
| Teva Investigational Site 13947 | Bellevue | Nebraska | 68123-4303 | — |
| Teva Investigational Site 13960 | Brick | New Jersey | 08724 | — |
| Teva Investigational Site 13932 | Piscataway | New Jersey | 08854 | — |
| Teva Investigational Site 13922 | Verona | New Jersey | 07044 | — |
| Teva Investigational Site 13945 | Rochester | New York | 14618 | — |
| Teva Investigational Site 13936 | High Point | North Carolina | 27262 | — |
| Teva Investigational Site 13953 | Cincinnati | Ohio | 45231 | — |
| Teva Investigational Site 13928 | Edmond | Oklahoma | 73034 | — |
| Teva Investigational Site 13955 | Oklahoma City | Oklahoma | 73131 | — |
| Teva Investigational Site 13949 | East Providence | Rhode Island | 02914 | — |
| Teva Investigational Site 13929 | Charleston | South Carolina | 29407 | — |
| Teva Investigational Site 13941 | Greenville | South Carolina | 29607 | — |
| Teva Investigational Site 13951 | Greenville | South Carolina | 29615 | — |
| Teva Investigational Site 13938 | Spartanburg | South Carolina | 29303 | — |
| Teva Investigational Site 13924 | Knoxville | Tennessee | 37909 | — |
| Teva Investigational Site 13962 | Boerne | Texas | 78006 | — |
| Teva Investigational Site 13920 | Dallas | Texas | 75231 | — |
| Teva Investigational Site 13930 | Houston | Texas | 77099 | — |
| Teva Investigational Site 13939 | San Antonio | Texas | 78230 | — |
| Teva Investigational Site 13957 | San Antonio | Texas | 78251 | — |
| Teva Investigational Site 13952 | South Burlington | Vermont | 05403 | — |
| Teva Investigational Site 13956 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02969408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02969408 live on ClinicalTrials.gov.